Press Releases

H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…

Swiss company Debio R.P. announces Agreement with Inhale subsidiary Shearwater Corporation

Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use

New pharmaceutical development company in Quebec : The SGF and the Swiss Group Debio create H3 BioDé

Partenariat entre l’Ecole de Pharmacie Genève-Lausanne (EPGL) et Debiopharm Group™ – L’Université et l’Industrie allient leurs forces

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology…

Dyax Corp. and Debiopharm S.A. report initiation of phase II clinical trial with EPI-HNE-4 for cystic fibrosis

Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use